Arbutus Biopharma
ABUS
ABUS
65 hedge funds and large institutions have $75.5M invested in Arbutus Biopharma in 2020 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
less ownership
Funds ownership: →
20% less call options, than puts
Call options by funds: $1.5M | Put options by funds: $1.87M
44% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 16
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
65
Holding in Top 10
–
Calls
$1.5M
Puts
$1.87M
Top Buyers
| 1 | +$10.4M | |
| 2 | +$6.26M | |
| 3 | +$2.6M | |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.05M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.3M |
Top Sellers
| 1 | -$12.1M | |
| 2 | -$4.41M | |
| 3 | -$4M | |
| 4 |
RI
RTW Investments
New York
|
-$2.79M |
| 5 |
Morgan Stanley
New York
|
-$1.39M |